Literature DB >> 33485303

Light chain deposition disease involving kidney and liver in a patient with IgD myeloma.

Takafumi Tsushima1, Tomo Suzuki2, Toshiki Terao1, Daisuke Miura1, Kentaro Narita1, Masami Takeuchi1, Akira Shimuzu3, Kosei Matsue4.   

Abstract

BACKGROUND: IgD multiple myeloma (MM) is a rare subtype of MM and light chain deposition disease (LCDD) outside the kidney is also a rare and has scarcely been reported. We report herein the details of the first reported case of LCDD involving the kidney and liver co-occurring with IgD myeloma. CASE
PRESENTATION: A 66-year-old female with IgD MM presented with rapidly progressive acute renal failure, ascites and pleural effusion. Immunofluorescent study of revealed the characteristic linear deposition of Igκ light chain along the glomerular and tubular basement membrane in kidney. Electron microscopy showed the powdery electron-dense deposits along the tubular and glomerular basement membrane consistent with the diagnosis of LCDD. Laser microdissection followed by mass spectrometry identified only Igκ light chain with more than 95% probability confirm the diagnosis of κ-LCDD but not heavy/light chain deposition disease. Liver biopsy with immunofluorescence study revealed the linear deposition of Igκ chain along the perisinusoidal space indicating the hepatic involvement of κ-LCDD. The patient was successfully treated with combination therapy with bortezomib, cyclophosphamide, dexamethasone, and daratumumab.
CONCLUSIONS: This report emphasizes that prompt biopsy of affected organs and initiation of clone directed therapy led to the correct diagnosis and favorable outcome in patient with LCDD who has extrarenal involvement.

Entities:  

Keywords:  CyBorD; Daratumumab; IgD myeloma; Light chain deposition disease; Liver involvement

Mesh:

Substances:

Year:  2021        PMID: 33485303      PMCID: PMC7824927          DOI: 10.1186/s12882-021-02246-9

Source DB:  PubMed          Journal:  BMC Nephrol        ISSN: 1471-2369            Impact factor:   2.388


  18 in total

Review 1.  The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases.

Authors:  Sanjeev Sethi; S Vincent Rajkumar; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2018-04-27       Impact factor: 10.121

2.  Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study.

Authors:  Florent Joly; Camille Cohen; Vincent Javaugue; Sébastien Bender; Mohamed Belmouaz; Bertrand Arnulf; Bertrand Knebelmann; Mathilde Nouvier; Vincent Audard; François Provot; Viviane Gnemmi; Dominique Nochy; Jean Michel Goujon; Arnaud Jaccard; Guy Touchard; Jean Paul Fermand; Christophe Sirac; Frank Bridoux
Journal:  Blood       Date:  2018-12-21       Impact factor: 22.113

3.  Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.

Authors:  César Samanez; Abel Domingo; M Teresa Cibeira; Rosa Miquel; Manel Soler; Joan Bladé
Journal:  Eur J Haematol       Date:  2006-01       Impact factor: 2.997

4.  Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.

Authors:  Camille Cohen; Bruno Royer; Vincent Javaugue; Raphael Szalat; Khalil El Karoui; Alexis Caulier; Bertrand Knebelmann; Arnaud Jaccard; Sylvie Chevret; Guy Touchard; Jean-Paul Fermand; Bertrand Arnulf; Frank Bridoux
Journal:  Kidney Int       Date:  2015-07-15       Impact factor: 10.612

5.  A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.

Authors:  Murielle Roussel; Giampaolo Merlini; Sylvie Chevret; Bertrand Arnulf; Anne Marie Stoppa; Aurore Perrot; Giovanni Palladini; Lionel Karlin; Bruno Royer; Antoine Huart; Margaret Macro; Pierre Morel; Laurent Frenzel; Cyrille Touzeau; Eileen Boyle; Véronique Dorvaux; Fabien Le Bras; David Lavergne; Frank Bridoux; Arnaud Jaccard
Journal:  Blood       Date:  2020-04-30       Impact factor: 22.113

6.  Renal monoclonal immunoglobulin deposition disease: the disease spectrum.

Authors:  Julie Lin; Glen S Markowitz; Anthony M Valeri; Neeraja Kambham; William H Sherman; Gerald B Appel; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2001-07       Impact factor: 10.121

7.  Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.

Authors:  Meera Mohan; Amy Buros; Pankaj Mathur; Neriman Gokden; Manisha Singh; Sandra Susanibar; Jorge Jo Kamimoto; Shadiqul Hoque; Muthukumar Radhakrishnan; Aasiya Matin; Cynthia Davis; Monica Grazziutti; Sharmilan Thanendrarajan; Frits van Rhee; Maurizio Zangari; Faith Davies; Gareth Morgan; Joshua Epstein; Bart Barlogie; Carolina Schinke
Journal:  Am J Hematol       Date:  2017-06-01       Impact factor: 10.047

8.  Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation.

Authors:  Ioannis Petrakis; Kostas Stylianou; Vasiliki Mavroeidi; Eleftheria Vardaki; Spyridon Stratigis; Stavros Stratakis; Irene Xylouri; Constantinos Perakis; Constantina Petraki; Lydia Nakopoulou; Eugene Daphnis
Journal:  Nephrol Dial Transplant       Date:  2010-02-03       Impact factor: 5.992

9.  Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases.

Authors:  J Bladé; J A Lust; R A Kyle
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

10.  Light-Chain Deposition Disease with Prominent Hepatic Involvement.

Authors:  Ana Cristino; Carmen Pais; Renata Silva; Paulo Carrola
Journal:  Eur J Case Rep Intern Med       Date:  2017-04-27
View more
  2 in total

1.  A case of light chain deposition disease involving the kidney with a normal serum free kappa/lambda light chain ratio.

Authors:  Suojian Zhang; Haifeng Ni; Qin Xu; Xiaoqin Cai; Haitao Li; Zhiqiang Wei; Juan Cao
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

2.  Light Chain Deposition Disease Diagnosed Using Computed Tomography-Guided Kidney Biopsy.

Authors:  Yoshinosuke Shimamura; Yayoi Ogawa; Hideki Takizawa; Toshiaki Hayashi; Yasuo Sakurai
Journal:  Cureus       Date:  2021-05-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.